Sexual Dysfunction in Women With Multiple Sclerosis (MS)

Ege University

Status: Enrolling

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting; Multiple Sclerosis; Fatigue in Multiple Sclerosis; Cognitive Dysfunction; Depression; Fatigue; Anxiety; Overactive Bladder; Sexual Disfunction

Study type: Observational

Funder types: Other

Identifiers

NCT07193823

24-5.1T/1

Details and patient eligibility

About

Sexual dysfunction in women with multiple sclerosis (MS) is an important yet often overlooked problem. The primary objective of this study is to investigate the prevalence of sexual dysfunction in female patients diagnosed with MS. The secondary objective is to evaluate the relationship between sexual dysfunction and fatigue, depression, anxiety, overactive bladder symptoms, and cognitive dysfunction.

For this purpose, the following validated instruments will be used: the Female Sexual Function Index (FSFI) to assess sexual dysfunction, the Brief International Cognitive Assessment for MS (BICAMS) to evaluate cognitive function, the Hospital Anxiety and Depression Scale (HADS) to assess depression and anxiety, the Fatigue Severity Scale (FSS) to measure fatigue, and the Overactive Bladder Questionnaire (OAB-V8) to evaluate overactive bladder symptoms.

Enrollment: 140 estimated patients

Sex: Female

Ages: 25 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female patients aged 25-50 years
• Literate and able to comprehend written and spoken instructions
• Diagnosed with relapsing-remitting form of multiple sclerosis
• Having a continuous/regular sexual partner
• Expanded Disability Status Scale (EDSS) score ≤ 5
• At least 3 months since the last relapse
• Sexually active within the past 3 months
• Spasticity level < grade 2 according to the Modified Ashworth Scale

Exclusion criteria

• Pregnancy
• Illiteracy or inability to understand spoken or written instructions
• Absence of a continuous/regular sexual partner
• Expanded Disability Status Scale (EDSS) score > 5
• Not sexually active within the past 3 months
• Spasticity level ≥ grade 2 according to the Modified Ashworth Scale

Trial design